Drugs / COVAC-2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05226702 | Jul 2022 → Nov 2023 | COVID-19 | University of Saskatchewan | Completed | No outcome recorded |
| Phase 1 | NCT04702178 | Feb 2021 → Nov 2022 | COVID-19 | University of Saskatchewan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05209009 | Aug 2022 → Mar 2024 | Orthocoronavirinae infectious disease | University of Saskatchewan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVAC-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05209009 ↗ |
| Modality | Vaccine | “VIDO has developed a vaccine called COVAC-2.” NCT04702178 ↗ |
| Route | Intramuscular | “Intramuscular vaccine against SARS-CoV-2” NCT04702178 ↗ |